title: The rationale for the use of parenteral omega-3 lipids in children with short bowel syndrome and liver disease.
abstract: Parenteral nutrition associated liver disease (PNALD) is the major source of morbidity and mortality in children with short bowel syndrome (SBS). There is emerging evidence that omega-6 fatty acids (omega6FA) within the parenteral solution play a major role in PNALD and their effects may be reversed or ameliorated by substitution with omega-3 fatty acids (omega3FA). This paper reviews the mechanisms whereby omega3FAs may influence PNALD by improving bile flow, inhibiting steatosis, and having immunomodulatory effects. The early clinical experience with omega3FAs in SBS and PNALD is briefly reviewed and the implications of such, and future directions are considered.
authors.affiliation: Group for Improvement of Intestinal Function and Treatment (GIFT), The Hospital for Sick Children, 555 University Avenue, Toronto, ON, Canada, M5G 1X8.
authors.forename: Ivan R
authors.initials: IR
authors.lastname: Diamond
authors.forename: Anca
authors.initials: A
authors.lastname: Sterescu
authors.forename: Paul B
authors.initials: PB
authors.lastname: Pencharz
authors.forename: Paul W
authors.initials: PW
authors.lastname: Wales
mesh_terms: D002648:Child; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage*; D006801:Humans; D008107:Liver Diseases / Q000209:etiology / Q000628:therapy*; D010288:Parenteral Nutrition / Q000379:methods*; D012778:Short Bowel Syndrome / Q000150:complications / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D015525:Fatty Acids, Omega-3